About Christopher Loose
Form D filings for Progentos Therapeutics in 2024 list Christopher Loose as CEO and director.
Christopher Loose first appears on SEC filings in 2024.
Experience
This experience comes from SEC filings. The years are when the filings name Christopher Loose in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Christopher Loose works with at each company, as listed on that company's latest Form D.
Progentos Therapeutics, Inc. · Form D, May 17, 2024
AM
Aleks Radovic-Moreno
Director
DH
Dmitrij Hristodorov
Director
DJ
Dan Janney
Director
CB
Cassidy Blundell
Director
SM
Sanjay Magavi
Executive officer
MT
Marc-Olivier Turgeon
Director